NCT01824459View on ClinicalTrials.gov

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

576

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions

Gastric Cancer

Interventions

DRUG

S-1

S-1：40\~60mg bid，d1\~14 q3W

DRUG

Oxaliplatin

oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W

DRUG

Cisplatin

cisplatin：60mg/m2，iv drip ，d1,q3W

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER

NCT01824459 - S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients | Biotech Hunter | Biotech Hunter